Cambridge Investment Research Advisors Inc. bought a new stake in Bausch Health Companies Inc (NYSE:BHC) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,884 shares of the company’s stock, valued at approximately $615,000.
Several other large investors also recently added to or reduced their stakes in BHC. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Bausch Health Companies by 0.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock valued at $156,267,000 after acquiring an additional 75,175 shares during the last quarter. Bank of Montreal Can lifted its position in shares of Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after acquiring an additional 815,311 shares during the period. Orbimed Advisors LLC lifted its position in shares of Bausch Health Companies by 89.1% in the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after acquiring an additional 1,696,400 shares during the period. Norges Bank bought a new stake in shares of Bausch Health Companies in the 4th quarter worth approximately $59,054,000. Finally, Thrivent Financial for Lutherans lifted its position in shares of Bausch Health Companies by 20.2% in the 4th quarter. Thrivent Financial for Lutherans now owns 2,592,825 shares of the company’s stock worth $47,890,000 after acquiring an additional 435,800 shares during the period. 53.67% of the stock is currently owned by institutional investors and hedge funds.
BHC has been the subject of a number of research reports. Wells Fargo & Co raised their price objective on Bausch Health Companies from $9.00 to $25.19 and gave the stock an “underperform” rating in a research report on Tuesday, February 19th. Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Thursday, February 14th. ValuEngine downgraded Bausch Health Companies from a “hold” rating to a “sell” rating in a research report on Saturday, April 13th. Bank of America reiterated an “underperform” rating and issued a $18.00 price objective on shares of Bausch Health Companies in a research report on Wednesday, March 20th. Finally, SunTrust Banks started coverage on Bausch Health Companies in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 target price for the company. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $27.65.
BHC stock opened at $22.13 on Wednesday. Bausch Health Companies Inc has a fifty-two week low of $17.20 and a fifty-two week high of $28.45. The firm has a market cap of $7.63 billion, a P/E ratio of 5.50, a price-to-earnings-growth ratio of 0.48 and a beta of 0.61. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.14. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the firm posted $0.89 EPS. The business’s revenue was up 1.1% on a year-over-year basis. As a group, equities research analysts expect that Bausch Health Companies Inc will post 4.15 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “24,884 Shares in Bausch Health Companies Inc (NYSE:BHC) Purchased by Cambridge Investment Research Advisors Inc.” was first reported by Modern Readers and is the property of of Modern Readers. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.modernreaders.com/news/2019/06/12/24884-shares-in-bausch-health-companies-inc-nysebhc-purchased-by-cambridge-investment-research-advisors-inc.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: Hedge Funds Explained
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.